Anticoagulants underused in high risk patients
The registry, funded by Bayer and run by an international steering committee led by the Thrombosis Research Institute in London, also found treatment was being overused in patients at lower risk.
“We have a global problem and it is certainly present in Australia,” vascular physician Professor Harry Gibbs said.
The GARFIELD registry (Global Anticoagulant Registry in the Field) started in 2009 prior to the entry of the new oral anticoagulants so the majority of assessed cases were on warfarin.
The first of five cohorts in the ongoing study – presented at the European Society of Cardiology congress in Munich last week – included 10,537 patients, in 19 countries, with non-valvular AF and at least one other risk factor for stroke. About 350 Australian patients were involved.
Of 6002 patients in cohort